Related Experiment Video

Updated: Aug 17, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

A management trial for Duchenne cardiomyopathy

Y Ishikawa1, J R Bach, Y Ishikawa

  • 1Department of Pediatrics, Sapporo University of Medicine, Hokkaido, Japan.

American Journal of Physical Medicine & Rehabilitation
|September 1, 1995
PubMed

Insights

Physicians can now prolong survival for individuals with neuromuscular disease. New treatments combining ACE inhibitors and beta-blockers show promise for managing muscular dystrophy-associated cardiomyopathy.

Area of Science:

  • Cardiology
  • Neurology
  • Pulmonology

Background:

  • Physiatrists can prolong survival in neuromuscular disease patients using respiratory aids.
  • Increased survival leads to higher morbidity and mortality from cardiomyopathy in generalized myopathies.

Purpose of the Study:

  • To evaluate the efficacy of novel therapeutic regimens for cardiomyopathy in patients with dystrophin-deficient muscular dystrophy.

Main Methods:

  • Retrospective analysis of 100 patients with muscular dystrophy and dilated cardiomyopathy (DCM).
  • Evaluation of digitalis and diuretics, followed by the addition of ACE inhibitors (enalapril) and beta-blockers in symptomatic patients.

Main Results:

  • Nine of 14 patients with DCM were asymptomatic on digitalis and diuretics, despite low left ventricular ejection fractions (LVEFs).
  • Five patients with symptomatic heart failure and severe ventricular dilatation showed improvement with the addition of ACE inhibitors and beta-blockers.
  • Two of these five patients died within one year.

Conclusions:

  • The combination of ACE inhibitors and beta-blockers may effectively manage muscular dystrophy-associated cardiomyopathy.
  • Further research is warranted to explore this combined therapeutic approach for muscular dystrophy-associated cardiomyopathy.

More Related Videos

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...